Method of building resistance to Covid-19 disease development. The strong link between the distribution of Covid-19 disease (CV) severity across the United States population and that of systemic inflammation, as indicated in the individual's C-reactive protein (CRP) level, explains the widely varied symptomatic responses of individuals afflicted with the virus. The data are consistent with the fewer infections and deaths reported for the Asian countries. The disease pathologies of CV and non-specific interstitial pneumonia (NSIP) patients bear close similarities. Modeling the disease as a chemically reactive process indicates that the virus catalyzes the inflammation driven reaction, causing lung infiltration and injury, up to and including patient death. Prevention methods involving exercise and diet successfully applied for lung stabilization in NSIP also apply to CV mitigation, the goal of which is to achieve pre-disease CRP levels of <10 mg/L, and preferably <3 mg/L, and more preferably <1 mg/L.
BUILDING RESILIENCE TO COVID-19 AND ITS VARIANTS